#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sjogren's syndrome B-cell small lymphocytic lymphoma refractory Leber's congenital amaurosis Gastrooesophageal cancer Hidradenitis White matter lesion Giant cell tumour of tendon sheath Ichthyosis Mantle cell lymphoma B-cell small lymphocytic lymphoma Head and neck cancer Urea cycle disorder Hyperinsulinaemic hypoglycaemia Transitional cell carcinoma Huntington's disease More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease – Treatment Advanced systemic mastocytosis Rhabdomyosarcoma – Treatment Haemophagocytic lymphohistiocytosis – Trials in Disease Amyotrophic lateral sclerosis – Trials in Disease Lymphangiosarcoma – Treatment MELAS syndrome – Life with Disease Gaucher’s disease type I – Life with Disease Congenital hypotransferrinaemia – Trials in Disease Aicardi-Goutieres syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Florquinitau (18F) Ponsegromab Isotretinoin Alisertib Sodium Iberdomide GSK5784283 NALOXEGOL Glutenin 2,4 DICHLOROBENZYL ALCOHOL Adrenaline Acid Tartrate Bp Montelukast Pyridoxine Hydrochloride Bp Cilastatin Pitavastatin Calcium Ibuprofen Sodium Dihydrate MB-CART2219.1 VTX2735 SODIUM Ipn01194 Delandistrogene Moxeparvovec Difelikefalin More therapies…

    Learn about Your Condition

    Critical illness Kaposi's sarcoma Diabetic foot Follicular lymphoma stage IV Genital infection female Hairy cell leukaemia recurrent B-cell lymphoma Mite allergy Basal cell naevus syndrome Pemphigus Phenylketonuria Systemic sclerosis pulmonary Fragile X syndrome Body mass index increased Overweight More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mzuxet Zjlwhsjt Kzmbh 2su Dkawrqxan 4axig Hdsvvfm

Want to learn more about this study or check if you can participate? Contact us.

  • FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

    Recruiting

    2 1
    Investigated Diseases:
    • Dry age-related macular degeneration
    Bulgaria Czechia France Germany Hungary Italy +3

  • Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Frexalimab
    • Tacrolimus
    Austria Belgium Czechia Denmark Finland France +6

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Capecitabine
    Austria Belgium Czechia France Germany Hungary +5

  • A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

    Recruiting

    3 1
    Investigated Diseases:
    • Lennox-Gastaut syndrome
    Investigated Drugs:
    • Clemizole Hydrochloride
    Czechia Hungary Italy Poland Romania Spain

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Sacituzumab Tirumotecan
    Austria Belgium Czechia Denmark Finland France +9

  • A study to evaluate the effectiveness and safety of AZD1163 in adults with moderate to severe rheumatoid arthritis

    Recruiting

    2 1
    Investigated Drugs:
    • AZD1163
    Bulgaria Germany Hungary Poland Spain

  • A study to evaluate the effectiveness of NNC0662-0419 and semaglutide in people with type 2 diabetes

    Recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Croatia Hungary Poland Portugal Slovakia Spain

  • A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • (S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE
    • Enfortumab Vedotin
    • Pembrolizumab
    Czechia Denmark France Germany Hungary Italy +3

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elritercept
    • Epoetin Alfa
    Belgium Bulgaria France Germany Greece Hungary +8

  • A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fenfluramine Hydrochloride
    Belgium France Germany Hungary Italy Poland +1
Previous Page
1 2 3 4 5 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!